-
2023-507338-26-00
5
2021-02-01
Histologically documented gastric or gastroesophageal junction adenoca
-
2024-515404-39-00
5
2021-01-14
Breast cancer
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2023-504828-25-00
9
2020-11-16
Chronic Lymphocytic Leukemia
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2023-504491-15-00
1
2020-10-30
Human epidermal growth factor receptor (HER2)-Expressing Cancers
-
2023-504805-35-00
9
2020-10-22
Lymphoma of B-cell origin
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2022-501522-38-00
5
2020-09-04
Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma
-
2022-502887-19-00
5
2020-08-18
Diffuse Large B-Cell Lymphoma
-
2024-512731-74-00
4
2020-07-03
multiple myeloma
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2023-507419-37-00
5
2020-06-25
Plasma cell myeloma
-
2023-506588-32-00
5
2020-06-12
Relapsed and Lenalidomide-Refractory Multiple Myeloma
-
2023-510455-28-00
5
2020-06-10
Hypereosinophilic Syndrome (HES)
-
2023-507703-63-00
9
2020-05-04
Pediatric Patients with Advanced RET-Altered Solid or Primary Central
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501973-37-00
5
2020-01-30
Endometrial cancer
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2023-506831-13-00
5
2020-01-15
haemophilia A (HA) without inhibitors and haemophilia B (HB) without i
-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2022-501102-35-00
5
2019-12-02
Early triple negative breast cancer
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer